Literature DB >> 23538750

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

X Zhao1, T Lwin, X Zhang, A Huang, J Wang, V E Marquez, S Chen-Kiang, W S Dalton, E Sotomayor, J Tao.   

Abstract

c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA (miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop linking overexpression of MYC, EZH2 and miRNA repression. Here, using a novel small-molecule BET bromodomain inhibitor, JQ1, and the EZH2 inhibitor, DZNep, we demonstrated that combined treatment of JQ1 and DZNep cooperatively disrupted MYC activation, resulting in a greater restoration of miR-26a expression and synergistically suppressed lymphoma growth and clonogenicity in aggressive lymphoma cells. Furthermore, CHIP assay demonstrated that MYC recruited EZH2 to miR-26a promoter and cooperatively repressed miR-26a expression in aggressive lymphoma cell lines, as well as primary lymphoma cells. Loss- or gain-of-function approaches revealed that miR-26a functioned as a tumor suppressor miRNA and mediated the combinatorial effects of JQ1 and DZNep. These findings represent a novel promising approach for silencing MYC-miRNA-EZH2 amplification loop for combinatorial therapy of aggressive B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23538750      PMCID: PMC4015113          DOI: 10.1038/leu.2013.94

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.

Authors:  H P Visser; M J Gunster; H C Kluin-Nelemans; E M Manders; F M Raaphorst; C J Meijer; R Willemze; A P Otte
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

Review 2.  MYC and aggressive B-cell lymphomas.

Authors:  Graham W Slack; Randy D Gascoyne
Journal:  Adv Anat Pathol       Date:  2011-05       Impact factor: 3.875

3.  EZH2 Y641 mutations in follicular lymphoma.

Authors:  C Bödör; C O'Riain; D Wrench; J Matthews; S Iyengar; H Tayyib; M Calaminici; A Clear; S Iqbal; H Quentmeier; H G Drexler; S Montoto; A T Lister; J G Gribben; A Matolcsy; J Fitzgibbon
Journal:  Leukemia       Date:  2011-01-14       Impact factor: 11.528

4.  Cell cycle activation by c-myc in a burkitt lymphoma model cell line.

Authors:  A Pajic; D Spitkovsky; B Christoph; B Kempkes; M Schuhmacher; M S Staege; M Brielmeier; J Ellwart; F Kohlhuber; G W Bornkamm; A Polack; D Eick
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

5.  Control of cell growth by c-Myc in the absence of cell division.

Authors:  M Schuhmacher; M S Staege; A Pajic; A Polack; U H Weidle; G W Bornkamm; D Eick; F Kohlhuber
Journal:  Curr Biol       Date:  1999-11-04       Impact factor: 10.834

6.  Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a.

Authors:  Tint Lwin; Jianhong Lin; Yong Sung Choi; Xinwei Zhang; Lynn C Moscinski; Kenneth L Wright; Eduardo M Sotomayor; William S Dalton; Jianguo Tao
Journal:  Blood       Date:  2010-09-14       Impact factor: 22.113

7.  Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.

Authors:  J Lin; T Lwin; J-J Zhao; W Tam; Y S Choi; L C Moscinski; W S Dalton; E M Sotomayor; K L Wright; J Tao
Journal:  Leukemia       Date:  2010-10-22       Impact factor: 11.528

8.  Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1.

Authors:  Vanessa J Craig; Sergio B Cogliatti; Jochen Imig; Christoph Renner; Stefan Neuenschwander; Hubert Rehrauer; Ralph Schlapbach; Stephan Dirnhofer; Alexander Tzankov; Anne Müller
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

9.  Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.

Authors:  N M Alajez; W Shi; A B Y Hui; J Bruce; M Lenarduzzi; E Ito; S Yue; B O'Sullivan; F-F Liu
Journal:  Cell Death Dis       Date:  2010-10-21       Impact factor: 8.469

10.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

View more
  53 in total

Review 1.  Polycomb genes, miRNA, and their deregulation in B-cell malignancies.

Authors:  Gang Greg Wang; Kyle D Konze; Jianguo Tao
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

Review 2.  MicroRNAs: master regulators of drug resistance, stemness, and metastasis.

Authors:  Umar Raza; Jitao David Zhang; Ozgür Sahin
Journal:  J Mol Med (Berl)       Date:  2014-02-09       Impact factor: 4.599

Review 3.  c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies.

Authors:  Jiangchuan Tao; Xiaohong Zhao; Jianguo Tao
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

Review 4.  Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

Authors:  Aristeidis Chaidos; Valentina Caputo; Anastasios Karadimitris
Journal:  Ther Adv Hematol       Date:  2015-06

5.  MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

Authors:  Anneleen Beckers; Gert Van Peer; Daniel R Carter; Moritz Gartlgruber; Carl Herrmann; Saurabh Agarwal; Hetty H Helsmoortel; Kristina Althoff; Jan J Molenaar; Belamy B Cheung; Johannes H Schulte; Yves Benoit; Jason M Shohet; Frank Westermann; Glenn M Marshall; Jo Vandesompele; Katleen De Preter; Frank Speleman
Journal:  Cancer Lett       Date:  2015-06-26       Impact factor: 8.679

6.  Emerging role of transcription factor-microRNA-target gene feed-forward loops in cancer.

Authors:  Qian Wu; Hua Qin; Qiu Zhao; Xing-Xing He
Journal:  Biomed Rep       Date:  2015-06-11

Review 7.  Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Authors:  Di Wen; Michael Danquah; Amit Kumar Chaudhary; Ram I Mahato
Journal:  J Control Release       Date:  2015-08-06       Impact factor: 9.776

8.  Targeting epigenetics for cancer prevention by dietary cancer preventive compounds--the case of miRNA.

Authors:  Ah-Ng Tony Kong; Chengyue Zhang; Zheng-Yuan Su
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-17

9.  Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8.

Authors:  Celestia Fang; Yu Qiao; Kyung-Hyun Park-Min; Lionel B Ivashkiv; Se Hwan Mun; Min Joon Lee; Koichi Murata; Seyeon Bae; Baohong Zhao
Journal:  J Immunol       Date:  2016-04-29       Impact factor: 5.422

10.  Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.

Authors:  Yi Hu; Huimin Liu; Chuanfeng Fang; Chen Li; Fjorela Xhyliu; Hayley Dysert; Juraj Bodo; Gabriel Habermehl; Benjamin E Russell; Wenjun Li; Marcia Chappell; Xiaofeng Jiang; Sarah L Ondrejka; Eric D Hsi; Jaroslaw P Maciejewski; Qing Yi; Kenneth C Anderson; Nikhil C Munshi; Geyou Ao; Jason N Valent; Jianhong Lin; Jianjun Zhao
Journal:  Cancer Res       Date:  2020-03-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.